Cargando…

Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease

Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a rare but fatal complication of TKI treatment. Transfer to chemotherapy or continuation with TKI of reduced dose are alternative treatment strategi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Qing, Chen, Liang-an
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220897/
https://www.ncbi.nlm.nih.gov/pubmed/22114570
http://dx.doi.org/10.1159/000332195
_version_ 1782217014495936512
author Tian, Qing
Chen, Liang-an
author_facet Tian, Qing
Chen, Liang-an
author_sort Tian, Qing
collection PubMed
description Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a rare but fatal complication of TKI treatment. Transfer to chemotherapy or continuation with TKI of reduced dose are alternative treatment strategies. We report a case of severe ILD in a non-small cell lung cancer patient treated with gefitinib. She experienced partial response with restarted low-dose EGFR-TKI erlotinib and corticosteroid treatment.
format Online
Article
Text
id pubmed-3220897
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-32208972011-11-23 Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease Tian, Qing Chen, Liang-an Case Rep Oncol Published: September 2011 Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a rare but fatal complication of TKI treatment. Transfer to chemotherapy or continuation with TKI of reduced dose are alternative treatment strategies. We report a case of severe ILD in a non-small cell lung cancer patient treated with gefitinib. She experienced partial response with restarted low-dose EGFR-TKI erlotinib and corticosteroid treatment. S. Karger AG 2011-09-16 /pmc/articles/PMC3220897/ /pubmed/22114570 http://dx.doi.org/10.1159/000332195 Text en Copyright © 2011 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published: September 2011
Tian, Qing
Chen, Liang-an
Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
title Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
title_full Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
title_fullStr Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
title_full_unstemmed Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
title_short Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
title_sort erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease
topic Published: September 2011
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220897/
https://www.ncbi.nlm.nih.gov/pubmed/22114570
http://dx.doi.org/10.1159/000332195
work_keys_str_mv AT tianqing erlotinibachievedpartialresponseinanonsmallcelllungcancerpatientwithgefitinibinducedinterstitiallungdisease
AT chenliangan erlotinibachievedpartialresponseinanonsmallcelllungcancerpatientwithgefitinibinducedinterstitiallungdisease